-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We keep our target at $125, 20.0x our 2027 EPS estimate. This is a discount to ABT's historical forward average despite strategic portfolio enhancement via the Exact Sciences (EXAS) deal and the strong innovation pipeline, in our view. We adjust our 2026 EPS view to $5.56 from $5.76 to include the dilution related to EXAS acquisition, and keep our 2027 EPS view at $6.26. ABT delivered significant pipeline milestones in Q1, highlighted by the earlier-than-planned approval and launch of two PFA catheters (Volt in the U.S. and Duo in Europe), completion of patient enrollment in the Catalyst left atrial appendage device trial, and positive trial results demonstrating Libre's benefits for Type 2 diabetes patients on basal insulin therapy. We also remain bullish on the integration of EXAS, which closed slightly earlier than anticipated in late March. The deal positions ABT as a leader in the ~$60B U.S. cancer screening & precision-oncology diagnostics market, which is one of health care's fastest-growing segments.